Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0ML8G
|
|||
Former ID |
DNCL003661
|
|||
Drug Name |
Turoctocog alfa
|
|||
Synonyms |
NN7008
Click to Show/Hide
|
|||
Indication | Haemophilia A [ICD-11: 3B10.0; ICD-9: 286] | Phase 3 | [1] | |
Company |
Novo Nordisk
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Coagulation factor VIII (F8) | Target Info | Modulator | [2] |
KEGG Pathway | Complement and coagulation cascades | |||
Panther Pathway | Blood coagulation | |||
Pathwhiz Pathway | Coagulation | |||
Reactome | Platelet degranulation | |||
Intrinsic Pathway of Fibrin Clot Formation | ||||
Common Pathway of Fibrin Clot Formation | ||||
COPII (Coat Protein 2) Mediated Vesicle Transport | ||||
Cargo concentration in the ER | ||||
WikiPathways | Complement and Coagulation Cascades | |||
Blood Clotting Cascade | ||||
Formation of Fibrin Clot (Clotting Cascade) |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01493778) Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A. U.S. National Institutes of Health. | |||
REF 2 | The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight ), in patients with hemophilia A. J Thromb Haemost. 2015 Mar;13(3):370-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.